Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Mitsuko Usui

Masakazu Mitsuhashi

Tyoku Matsuhashi

Shunsaku Ando

Shunsaku Koyama

Akio Yamamoto

Tyoku Matuhashi

A novel hyposensitization agent was prepared by covalently attaching a saccharide to a cedar pollen allergen having a partial amino acid sequence of Ala-Ile-Asn-Ile-Phe-Asn- beginning at its N-terminal. The hyposensitization agent, when compared with an intact cedar pollen allergen, extremely accelerates the production of immunoglobulin G and M antibodies which are specific to intact cedar pollen allergen, but extremely reduces the production of immunoglobulin E antibody which is specific to the allergen. Thus, the hyposensitization agent is administrable to cedar pollinosis patients with no anaphylaxis and allergy, and cuts hyposensitization period to about 1/3 to 1/200.

Hyposensitization agent

A novel hyposensitization agent was prepared by covalently attaching a saccharide, e.g. homo- and heteroglycans, for example, starch, amylose, dextran, polysucrose, pullulan, elsinan, curdlan, gum arabic, gum tragacanth, guar gum, xanthan gum carrageenan, pectin, cellulose, glucomannan, chitosan, and lipopolysaccharide, and their derivatives and partial hydrolysates to, a cedar pollen allergen. The hyposensitization agent can be administered to a cedar pollinosis patient without fear of eliciting anaphylaxis and allergy within a shortened hyposensitization period because the hyposensitization agent much more enhances the production of immunoglobulin G and M antibodies which are specific to intact cedar pollen allergen, but extremely reduces the production of immunoglobulin E antibody which is specific to the allergen and responsible for anaphylaxis and allergy.

Hyposensitization agent of cedar pollen antigen

The present invention relates to a process for the production of vaccine, characterized by covalent attachment of a biologically toxic substance to a saccharide both to form a biologically toxic substance-saccharide conjugate and to detoxify said substance, followed by collection of the formed conjugate. According to the invention, various vaccine products having a high productivity of immunoglobulin G and M antibodies, but without productivity of immunoglobulin E antibody, are easily obtainable. In addition, the vaccine products, upon administration to animals, do not effect any allergic reaction and/or anaphylactic-shock due to the lack of the immunoglobulin E antibody production.

Growing community of inventors

Okayama, Japan

Mitsuko Usui